26.10
Precedente Chiudi:
$23.56
Aprire:
$23.02
Volume 24 ore:
300.67K
Relative Volume:
0.68
Capitalizzazione di mercato:
$364.37M
Reddito:
-
Utile/perdita netta:
$-8.89M
Rapporto P/E:
-37.29
EPS:
-0.7
Flusso di cassa netto:
$-6.48M
1 W Prestazione:
+5.14%
1M Prestazione:
+79.55%
6M Prestazione:
+127.68%
1 anno Prestazione:
+101.23%
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Nome
Greenwich Lifesciences Inc
Settore
Industria
Telefono
203-434-3290
Indirizzo
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Confronta GLSI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
GLSI
Greenwich Lifesciences Inc
|
26.30 | 326.41M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.46 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.16 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
823.85 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.91 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.31 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-20 | Iniziato | Noble Capital Markets | Outperform |
| 2021-09-01 | Iniziato | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Borsa (GLSI) Ultime notizie
Behavioral Patterns of GLSI and Institutional Flows - Stock Traders Daily
FDA approves commercial GP2 lot for Greenwich’s breast cancer trial By Investing.com - Investing.com Canada
Why Did Greenwich LifeSciences Stock Soar Pre-Market Today? - Asianet Newsable
GLSI Stock Surges Pre-Market On Clearing FDA Manufacturing Step For Its Breast Cancer Trial - Stocktwits
Greenwich LifeSciences stock soars after FDA approves commercial GP2 in trial - Investing.com Canada
Greenwich gets FDA nod for commercially made product candidate - Seeking Alpha
Greenwich LifeSciences surges as FDA clears supplies for breast cancer trial - TradingView — Track All Markets
Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01 - The Manila Times
FDA approves first GP2 batch for breast cancer trial, 200,000 doses - Stock Titan
Head to Head Contrast: Greenwich LifeSciences (NASDAQ:GLSI) & Vertex Pharmaceuticals (NASDAQ:VRTX) - Defense World
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 1,800 Shares of Stock - MarketBeat
Greenwich LifeSciences CEO Patel buys $53,694 in GLSI stock By Investing.com - Investing.com Canada
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush - Baystreet.ca
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases 2,900 Shares of Stock - MarketBeat
Greenwich LifeSciences CEO Patel buys $79,866 in GLSI stock By Investing.com - Investing.com South Africa
Greenwich LifeSciences CEO Patel buys $79,866 in GLSI stock - Investing.com
Greenwich LifeSciences (GLSI) Price Target Increased by 13.10% to 48.45 - Nasdaq
Chart Watch: Will Greenwich LifeSciences Inc stock benefit from commodity pricesJuly 2025 Reactions & Entry Point Confirmation Signals - Bộ Nội Vụ
Technical Analysis: Is Greenwich LifeSciences Inc stock ready for breakoutTrade Exit Summary & Reliable Price Action Trade Plans - Bộ Nội Vụ
Why is GLSI stock rising today? - MSN
HER2-Positive Breast Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Roche Pharma AG, Dizal Pharma, Greenwich LifeSciences, Ambrx - The Globe and Mail
Will Greenwich LifeSciences Inc. stock outperform growth indexesJuly 2025 Selloffs & Accurate Intraday Trading Signals - Улправда
Why Greenwich LifeSciences Inc. stock is a must watch in 2025Volume Weighted Average Price & Smart Beta Strategies That Actually Work - Улправда
How $594B in Precision Tech is Cracking the Metastatic Cancer Code - The Globe and Mail
Snehal Patel Buys Handful Of Shares In Greenwich LifeSciences - simplywall.st
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Acquires 4,300 Shares - Defense World
Will Greenwich LifeSciences Inc. stock benefit from upcoming earnings reports2026 world cup usa national team group stage star players transition play group prediction preview - ulpravda.ru
A US$74m drop in the market cap of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is not what insiders like to see after purchasing shares recently - simplywall.st
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 4,300 Shares of Stock - MarketBeat
Head-To-Head Analysis: Greenwich LifeSciences (NASDAQ:GLSI) vs. Avalon GloboCare (NASDAQ:ALBT) - Defense World
Snehal Patel Purchases 2,900 Shares of Greenwich LifeSciences (NASDAQ:GLSI) Stock - Defense World
Is Lehar Footwears Limited Poised for a PostEarnings RallyVolatility Adjusted Trading & Free Exceptional Risk Adjusted Gains - earlytimes.in
Insider Buying: Snehal Patel Acquires Additional Shares of Green - GuruFocus
Patel, Greenwich Lifesciences CEO, buys $63k in GLSI stock By Investing.com - Investing.com Nigeria
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Buys 2,900 Shares - MarketBeat
Patel, Greenwich Lifesciences CEO, buys $63k in GLSI stock - Investing.com
FY2025 Earnings Estimate for GLSI Issued By HC Wainwright - MarketBeat
How (GLSI) Movements Inform Risk Allocation Models - Stock Traders Daily
New milestone in breast cancer prevention claimed by Greenwich - The Pharma Letter
Greenwich LifeSciences stock soars after extending insider lock-up By Investing.com - Investing.com India
Greenwich LifeSciences extends insider share lock-up to Sept 2026 By Investing.com - Investing.com Nigeria
Greenwich LifeSciences stock soars after extending insider lock-up - Investing.com
What's Going On With Greenwich LifeSciences Stock Monday? - One News Page
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Greenwich LifeSciences Takes Flight As FLAMINGO 01 Breast Cancer Trial Progresses - Nasdaq
Why Did GLSI Stock Surge 25% Today? - Stocktwits
Greenwich LifeSciences extends lock-up of shares to September 2026 - marketscreener.com
Greenwich LifeSciences Extends Lock-Up Of Shares To September 2026 - TradingView — Track All Markets
Greenwich LifeSciences Extends Share Lock-Up to September For Directors, Officers - marketscreener.com
Greenwich LifeSciences extends insider share lock-up to Sept 2026 - Investing.com
Greenwich Lifesciences Inc Azioni (GLSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):